Gyre Therapeutics, Inc. GYRE Equity Gain Loss Of Unconsolidated Affiliates
Equity Gain Loss Of Unconsolidated Affiliates at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:EquityGainLossOfUnconsolidatedAffiliates.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s equity gain loss of unconsolidated affiliates.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s equity gain loss of unconsolidated affiliates?
- Gyre Therapeutics, Inc. (GYRE) reported equity gain loss of unconsolidated affiliates of -$21K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s equity gain loss of unconsolidated affiliates changed year-over-year?
- Gyre Therapeutics, Inc.'s equity gain loss of unconsolidated affiliates decreased by 10.5% year-over-year, from -$19K to -$21K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s equity gain loss of unconsolidated affiliates?
- Over 2 years (2022 to 2025), Gyre Therapeutics, Inc.'s equity gain loss of unconsolidated affiliates has grown at a -44.6% compound annual growth rate (CAGR), from -$251K to -$77K.
- What does equity gain loss of unconsolidated affiliates mean?
- Reflects the company's share of the net income or loss from investments in entities where it holds significant influence but not full control. This metric provides insight into the performance of strategic partnerships and joint ventures. It is a key indicator of the value generated by non-consolidated business interests.